Influenza, Obesity, Type 2 diabetes
Conditions
Brief summary
Hemaglutinnin Inhibition Assay GMTs at day 0 (pre-vaccination) and at 14 days post-vaccination with Vaxigrip., The proportion of participants achieving a protective hemagluttinin inhibition assay titre ≥40 at 14 days post-vaccination., The proportion of participants achieving a four-fold rise in hemagluttinin inhibition assay titre at 14 days post-vaccination.
Detailed description
Incidence of solicited local (injection site) and systemic AEs in the 7-days post-vaccination., Incidence of SAEs, unsolicited AEs and fatal AEs during the period of the study.
Interventions
DRUGVaxigrip injektionsvätska
DRUGsuspension
DRUGi förfylld spruta.
Trivalent influensavaccin (spjälkat virus
DRUGinaktiverat).
Sponsors
Region Stockholm – SLSO
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemaglutinnin Inhibition Assay GMTs at day 0 (pre-vaccination) and at 14 days post-vaccination with Vaxigrip., The proportion of participants achieving a protective hemagluttinin inhibition assay titre ≥40 at 14 days post-vaccination., The proportion of participants achieving a four-fold rise in hemagluttinin inhibition assay titre at 14 days post-vaccination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of solicited local (injection site) and systemic AEs in the 7-days post-vaccination., Incidence of SAEs, unsolicited AEs and fatal AEs during the period of the study. | — |
Countries
Sweden
Outcome results
None listed